BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for lynch syndrome

American Journal of Surgical Pathology

Volumn 37, Issue 10, 2013, Pages 1592-1602

  Toon, Christopher W ^a,b   Walsh, Michael D ^g,h   Chou, Angela ^d,e   Capper, David ^j,k   Clarkson, Adele ^a   Sioson, Loretta ^a   Clarke, Stephen ^b,c   Mead, Scott ^d,e   Walters, Rhiannon J ^h   Clendenning, Mark ^h   Rosty, Christophe ^a,h   Young, Joanne P ^h   Win, Aung Ko ⁱ   Hopper, John L ⁱ   Crook, Ashley ^c   Von Deimling, Andreas ^j,k   Jenkins, Mark A ⁱ   Buchanan, Daniel D ^h   Gill, Anthony J ^a,b,f  

^a Department of Anatomical Pathology ^*

^b Northern Translational Cancer Research Unit   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

BRAFV600E; Lynch syndrome; Microsatellite instability; Mismatch repair deficiency; MMR; MSI; VE1 immunohistochemistry

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ALGORITHM; ARTICLE; FEMALE; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; TISSUE MICROARRAY;

ALGORITHMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MICROSATELLITE INSTABILITY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TISSUE ARRAY ANALYSIS;

EID: 84884513645     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31828f233d     Document Type: Article

References (42)

1. American Cancer Society, Colorectal Cancer Facts and Figures 2011-2013. Available at: http://www.cancer.org/research/cancerfacts figures/ colorectalcancerfactsfigures/colorectal-cancer-facts-figures-2011-2013-page. Accessed April 1 2013.
2. Beamer LC, Grant ML, Espenshied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30:1058-1063.
3. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783-5788.
4. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009; 11:42-65.
5. Jarvinen HJ, Aamio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118: 829-834.
6. Hampel H. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Cancer Netw. 2010;8:597-601.
7. Hall MJ. Counterpoint: implementing population genetic screening for Lynch Syndrome among newly diagnosed colorectal cancer patients-will the ends justify the means? J Natl Compr Cancer Netw. 2010;8:606-611.
8. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009;11:3-14.
9. Kastrinos F, Syngal S. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? J Clin Oncol. 2012;30: 1024-1027.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
11. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
12. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006;5:2.
13. Tanaka H, Deng G, Matsuzaki K, et al. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer. 2006;118:2765-2771.
14. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010;16:790-799.
15. Kakar S, Deng G, Sahai V, et al. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. Arch Pathol Lab Med. 2008;132:958-964.
16. Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012;55:128-133.
17. Maestro ML, Vidaurreta M, Sanz-Casla MT, et al. Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. Ann Surg Oncol. 2007;14:1229-1236.
18. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CA LGB 89803. Clin Cancer Res. 2012;18:890-900.
19. Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012;36:744-752.
20. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466-474.
21. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063-6069.
22. Zlobec I, Bihl MP, Schwarb H, et al. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010;127: 367-380.
23. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
24. NCCN. Clinical Practice Guidelines in Oncology Colon Cancer. Version2013. Available at http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed April 1, 2013.
25. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
26. Koperek O, Komauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
27. Bullock M, O'Neill C, Chou A, et al. Utilisation of a monoclonal antibody for BRAFV600E detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012;19:779-784.
28. Skorokhod A, Capper D, von Deimling A, et al. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol. 2012;67:488-491.
29. Preusser M, Capper D, Berghoff AS, et al. Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol. 2012;21:159-164.
30. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36:1796-1800.
31. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038-2040.
32. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.
33. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumors of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010.
34. Edge SE, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
35. James MR, Dumeni T, Stark MS, et al. Rapid screening of 4000 individuals for germ-line variations in the BRAF gene. Clin Chem. 2006;52:1675-1678.
36. Buchanan DD, Sweet K, Drini M, et al. Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. PLoS One. 2010;5:e11636.
37. Newcomb PA, Baron J, Cotterchio M, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2331-2343.
38. Walsh MD, Buchanan DD, Pearson SA, et al. Immunohistochemical testing of conventional adenomas for loss of expression of mismatch repair proteins in Lynch syndrome mutation carriers: a case series from the Australasian site of the colon cancer family registry. Mod Pathol. 2012;25:722-730.
39. Lang AH, Drexel H, Geller-Rhomberg S, et al. Optimized allelespecific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn. 2011;13:23-28.
40. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as firstline screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33:1639-1645.
41. Hall G, Clarkson A, Shi A, et al. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology. 2010;42:409-413.
42. Mojtahed A, Schrijver I, Ford JM, et al. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011;24:1004-1014.